Table 1.
Baseline characteristics.
| Variables | AnH = 181 | AwH = 79 | p-value | |
|---|---|---|---|---|
| Male, n (%) | 70 (38.7) | 41 (51.9) | 0.047 | |
| Age, years | 56 (45–63) | 64.5 (56–72) | <0.001 | |
| BMI, Kg/m2 | 24 (22.0–27.3) | 27 (24.5–32.0) | <0.001 | |
| Smoking habit, n (%) | Never-smoker | 114 (62.9) | 42 (53.2) | 0.184 |
| Current smoker | 10 (5.6) | 6 (7.6) | ||
| Former smoker | 57 (31.5) | 31 (39.2) | ||
| Age Asthma Onset, median (IQR) | 42 (23.3–55.0) | 55 (45.0–66.0) | <0.001 | |
| Atopy, n (%) | 113 (62.4) | 41 (51.9) | 0.112 | |
| ICS, n (%) | 163 (90.0) | 71 (89.9) | 0.964 | |
| LTRA, n (%) | 59 (32.6) | 32 (40.5) | 0.230 | |
| mOCS, n (%) | 32 (17.8) | 11 (13.9) | 0.453 | |
| Step GINA, n (%) | 1 | 16 (8.8) | 7 (8.8) | 0.947 |
| 2 | 4 (2.2) | 2 (2.5) | ||
| 3 | 27 (14.9) | 12 (15.2) | ||
| 4 | 51 (28.2) | 19 (24.1) | ||
| 5 | 83 (45.9) | 39 (49.4) | ||
| Beclomethasone HFA equivalent, median (IQR) | 400 (320–800) | 440 (320–800) | 0.520 | |
| MART treatment, n (%) | 92 (50.8) | 40 (50.6) | 0.977 | |
| ACQ, median (IQR) | 0.5 (0.0–1.50) | 0.33 (0.0–1.00) | 0.081 | |
| Exacerbations (previous year), n (%) | 83 (45.9) | 33 (41.8) | 0.518 | |
| Mild Exacerbations, median (IQR) | 0 (0–2) | 0 (0–2) | 0.929 | |
| Severe Exacerbations, median (IQR) | 0 (0–0) | 0 (0–0) | 0.689 | |
| Healthcare utilization, n (%) | 79 (43.6) | 25 (31.6) | 0.064 | |
Data are presented as number (n) and percentage (%) for dichotomous values or median (IQR) for skewed variables. AnH, asthma no hypertension; AwH, asthma with hypertension; IQR, inter-quartile range; BMI, body mass index; ICS, inhaled corticosteroids; LTRA, Leukotriene Receptor Antagonists; mOCS, maintenance oral corticosteroids; GINA, Global Initiative for Asthma; HFA, hydrofluoroalkane; MART, Maintenance and Reliever Therapy; ACQ, Asthma Control Questionnaire. Bold p-value <0.05.